Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00624351 · ClinicalTrials.gov registry record · Phase 2

Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease

A Phase 2 study of Systemic Lupus Erythematosus, sponsored by UCB Pharma.

Completed
Registry status
Phase 2
Development phase
227
Enrollment target
20
Study locations

NCT00624351 is a Phase 2 study of Systemic Lupus Erythematosus that has completed, run by UCB Pharma. The registered enrollment target is 227 participants, below the 378-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (40% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00624351, a Phase 2 study of Systemic Lupus Erythematosus, has completed, sponsored by UCB Pharma.

COMPLETED
Registry status
Phase 2
Development phase
227 participants
Enrollment target
20
Study locations

Study Summary

The primary objective of the study is to assess the dose response and the dose frequency of epratuzumab in patients with SLE.

Conditions Studied

Systemic Lupus Erythematosus

Interventions

  • OTHER Placebo
  • BIOLOGICAL Epratuzumab

Study Locations (20)

North Carolina

  • - Chapel Hill
  • - Charlotte
  • - Durham
  • - Wilmington

California

  • - La Jolla
  • - Los Angeles
  • - San Leandro

Florida

  • - Aventura
  • - Tampa

Alabama

  • - Birmingham

Arizona

  • - Tucson

Colorado

  • - Denver

Connecticut

  • - Farmington

Maryland

  • - Baltimore

Trial Details

FieldValue
Enrollment Target 227 participants
Start Date 2008-01
Est. Completion 2009-08
Phase Phase 2

Sponsor

UCB Pharma

100 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00624351

The ClinicalTrials.gov registry entry for NCT00624351 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 227 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 378-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (40% lower). The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00624351 reports 20 study locations spanning 14 distinct geographic areas - top geographies include North Carolina, California, Florida.

Frequently Asked Questions

What is clinical trial NCT00624351 about?

NCT00624351 is a clinical study titled "Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease". The primary objective of the study is to assess the dose response and the dose frequency of epratuzumab in patients with SLE.

What is the current status of trial NCT00624351?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 227 participants. The study started on 2008-01. Estimated completion is 2009-08.

What conditions does trial NCT00624351 study?

This clinical trial studies the following conditions: Systemic Lupus Erythematosus.

What interventions are being tested in trial NCT00624351?

The interventions under investigation include: Placebo (OTHER), Epratuzumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT00624351?

This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00624351 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Systemic Lupus Erythematosus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Systemic Lupus Erythematosus

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.